Back to Sectors

AUPH

Aurinia Pharmaceuticals Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 80% | 5/7/2026 | margin expansionNEUTRAL | 70% | 5/7/2026 | acquisitionBULLISH | 60% | 5/7/2026 | buybackNEUTRAL | 50% | 5/7/2026 | management changeBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 80% | 5/7/2026 | margin expansionNEUTRAL | 70% | 5/7/2026 | acquisitionBULLISH | 60% | 5/7/2026 | buybackNEUTRAL | 50% | 5/7/2026 | management changeBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 80% | 5/7/2026 | margin expansionNEUTRAL | 70% | 5/7/2026 | acquisitionBULLISH | 60% | 5/7/2026 | buybackNEUTRAL | 50% | 5/7/2026 | management changeBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 80% | 5/7/2026 | margin expansionNEUTRAL | 70% | 5/7/2026 | acquisitionBULLISH | 60% | 5/7/2026 | buybackNEUTRAL | 50% | 5/7/2026 | management changeBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 80% | 5/7/2026 | margin expansionNEUTRAL | 70% | 5/7/2026 | acquisitionBULLISH | 60% | 5/7/2026 | buybackNEUTRAL | 50% | 5/7/2026 | management changeBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 80% | 5/7/2026 | margin expansionNEUTRAL | 70% | 5/7/2026 | acquisitionBULLISH | 60% | 5/7/2026 | buybackNEUTRAL | 50% | 5/7/2026 | management changeBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 80% | 5/7/2026 | margin expansionNEUTRAL | 70% | 5/7/2026 | acquisitionBULLISH | 60% | 5/7/2026 | buybackNEUTRAL | 50% | 5/7/2026 | management changeMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 7

Net income rose to $34.4 million, driven by 24% revenue growth.

earnings beat
90%
bullishMay 7

Gross margins expanded to 92% due to manufacturing efficiencies.

margin expansion
80%
neutralMay 7

Agreement to acquire Kezar Life Sciences for $6.955 billion.

acquisition
70%
bullishMay 7

Repurchased 2.5 million shares for $36.2 million in the quarter.

buyback
60%
neutralMay 7

Complete replacement of CEO, COO, and CFO in March 2026.

management change
50%
bullishMay 7

Net income rose to $34.4 million, driven by 24% revenue growth.

earnings beat
90%
bullishMay 7

Gross margins expanded to 92% due to manufacturing efficiencies.

margin expansion
80%
neutralMay 7

Agreement to acquire Kezar Life Sciences for $6.955 billion.

acquisition
70%
bullishMay 7

Repurchased 2.5 million shares for $36.2 million in the quarter.

buyback
60%
neutralMay 7

Complete replacement of CEO, COO, and CFO in March 2026.

management change
50%
bullishMay 7

Net income rose to $34.4 million, driven by 24% revenue growth.

earnings beat
90%
bullishMay 7

Gross margins expanded to 92% due to manufacturing efficiencies.

margin expansion
80%
neutralMay 7

Agreement to acquire Kezar Life Sciences for $6.955 billion.

acquisition
70%
bullishMay 7

Repurchased 2.5 million shares for $36.2 million in the quarter.

buyback
60%
neutralMay 7

Complete replacement of CEO, COO, and CFO in March 2026.

management change
50%
bullishMay 7

Net income rose to $34.4 million, driven by 24% revenue growth.

earnings beat
90%
bullishMay 7

Gross margins expanded to 92% due to manufacturing efficiencies.

margin expansion
80%
neutralMay 7

Agreement to acquire Kezar Life Sciences for $6.955 billion.

acquisition
70%
bullishMay 7

Repurchased 2.5 million shares for $36.2 million in the quarter.

buyback
60%
neutralMay 7

Complete replacement of CEO, COO, and CFO in March 2026.

management change
50%
bullishMay 7

Net income rose to $34.4 million, driven by 24% revenue growth.

earnings beat
90%
bullishMay 7

Gross margins expanded to 92% due to manufacturing efficiencies.

margin expansion
80%
neutralMay 7

Agreement to acquire Kezar Life Sciences for $6.955 billion.

acquisition
70%
bullishMay 7

Repurchased 2.5 million shares for $36.2 million in the quarter.

buyback
60%
neutralMay 7

Complete replacement of CEO, COO, and CFO in March 2026.

management change
50%
bullishMay 7

Net income rose to $34.4 million, driven by 24% revenue growth.

earnings beat
90%
bullishMay 7

Gross margins expanded to 92% due to manufacturing efficiencies.

margin expansion
80%
neutralMay 7

Agreement to acquire Kezar Life Sciences for $6.955 billion.

acquisition
70%
bullishMay 7

Repurchased 2.5 million shares for $36.2 million in the quarter.

buyback
60%
neutralMay 7

Complete replacement of CEO, COO, and CFO in March 2026.

management change
50%
bullishMay 7

Net income rose to $34.4 million, driven by 24% revenue growth.

earnings beat
90%
bullishMay 7

Gross margins expanded to 92% due to manufacturing efficiencies.

margin expansion
80%
neutralMay 7

Agreement to acquire Kezar Life Sciences for $6.955 billion.

acquisition
70%
bullishMay 7

Repurchased 2.5 million shares for $36.2 million in the quarter.

buyback
60%
neutralMay 7

Complete replacement of CEO, COO, and CFO in March 2026.

management change
50%

Filing History

10-QMay 7, 2026

The Q1 2026 filing reveals a company in a state of high-stakes transition. On one hand, the commercial success of LUPKYNIS is undeniable, with accelerating market penetration and impressive margin expansion proving the viability of the business model. The shift toward profitability is clear, and the company's ability to generate significant operating cash flow provides a strong tailwind for organic growth. However, the sudden overhaul of the executive leadership team in March 2026 and the announcement of a massive merger with Kezar Life Sciences introduce significant execution risk. Investors must weigh the strength of the current income statement against a rapidly depleting cash balance and the looming financing requirements of a multi-billion dollar acquisition. The overall impact of the filing is a shift from a focus on clinical success to a focus on capital allocation and M&A integration.